Study of a medicine to assess safety, effects, and how it works in the body of children with chronic kidney disease

Prospective open-label interventional clinical trial evaluating the efficacy, safety, and pharmacokinetics of SGLT-2 inhibitors in pediatrics with chronic kidney disease

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202511687575219

Enrollment

Registered

2025-11-24

Start date

2025-12-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genetic Diseases Paediatrics Kidney Disease

Interventions

Dapagliflozin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age 2–18 years with CKD stages 2–4 (eGFR 15–89 mL/min/1.73 m²). Proteinuria/elevated albuminuria (uACR or uPCR >0.2 mg/mg).

Exclusion criteria

Exclusion criteria: Diabetic children. Acute kidney injury <3 months. Pregnancy. Patients with known contraindications.

Design outcomes

Primary

Measure	Time frame
Evaluate change in eGFR slope over study duration.	—

Secondary

Measure	Time frame
Assess change in urine albumin/creatinine or protein/creatinine ratio, safety, blood pressure, growth parameters and drug pharmacokinetics.	—

Countries

Egypt

Contacts

Public ContactAhmed;Noha El Koraey;Hamdy

Professor of Internal Medicine and Head of Nephrology and Kidney Transplantation Department Alexandria University Hospital;Acting head of Clinical Pharmacy and Pharmacy Practice Department Faculty of Pharmacy Alexandria University

drahmed@hotmail.com;noha.alaaeldine@alexu.edu.eg0201000304563;0201005182151

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026